The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXI.e

Rechallenge may not necessarily lead to relapse of AE/ILD

Publications

Tungjitviboonkun S, Bumrungratanayos N, Jitwimungsanon J

Erlotinib-associated interstitial pneumonitis with successful readministration.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Jul 19;;10781552231190319 — 2023 Jul 19 — 10781552231190319

Dallas JL, Jantz MA, Lightsey JL, Sonntag C, Kaye FJ

Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Jun;6;1142-3 — 2011 Jun — 1142-3